A novel self-amplifying RNA
The novel RuV-based saRNA, leveraging the rubella virus replicon, addresses the challenges of size and immune activation in existing saRNA vaccines by enhancing antigen expression and safety, enabling effective immune responses and therapeutic applications.
Patent Information
- Application Number
- PCT/SG2024/050350
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-28
AI Technical Summary
Current self-amplifying RNA (saRNA) vaccines face challenges due to their large size and immune activation, leading to adverse effects and restricted antigen expression, necessitating a safer alternative with improved efficiency.
A novel saRNA utilizing the rubella virus replicon, specifically the RuV RA27/3 strain, is developed, incorporating specific polynucleotides and structural elements to enhance antigen expression while reducing immune activation and adverse events.
The RuV-based saRNA demonstrates effective antigen expression with a better safety profile, inducing potent immune responses at lower doses and potentially offering improved therapeutic outcomes for vaccines and cancer therapy.
Smart Images

Figure SG2024050350_28112024_PF_FP_ABST
Abstract
Description
[0001] A NOVEL SELF-AMPLIFYING RNA
[0002] CROSS-REFERENCE TO RELATED APPLICATION
[0003] This application claims priority of Singapore Patent Application No. 10202301453Q filed on
[0004] May 24, 2023, the contents of which are incorporated herein in their entirety by reference.
[0005] FIELD OF THE INVENTION
[0006] The present disclosure relates to a novel self-amplifying RNA (saRNA) having an improved safety profile and capable of effectively expressing a protein of interest. The disclosure also relates to the use of the saRNA in vaccine and cancer therapy.
[0007] BACKGROUND OF THE INVENTION
[0008] RNA based therapeutics have received tremendous attention as a result of the COVID-19 mRNA vaccines. Conventional non-replicating mRNA-based therapeutics are in vitro transcribed RNAs encoding viral proteins such as Moderna or BioNTech-Pfizer COVID-19 vaccine or therapeutic proteins, such as antibodies or immune modulators for immunotherapy. They may incorporate chemically modified nucleotides, sequence optimization, and different purification strategies to improve efficiency of mRNA translation and reduce intrinsic immunogenic properties. However, a limitation to mRNA-based therapies is that the amount of antigen or antibody delivered is proportional to the number of conventional mRNA transcripts successfully delivered. Therefore, to achieve adequate expression for protection or immunomodulation may require large or repeat dose resulting in increased risk of adverse effects.
[0009] Unlike mRNA-based therapies, self-amplifying RNAs (saRNAs) contain an autoreplicative ability because of a virus-derived replicon. saRNAs have shown potential as vaccine vectors for infectious agents including the causative virus of the COVID-19 pandemic (SARS-CoV-2) and some clinical trials for influenza and rabies. Preclinical research has shown that saRNA vaccines are able to induce equivalent or more potent immune responses at lower doses compared to those achieved by non-replicating mRNA vaccines because of its autoreplicative properties of the viral replicon backbone. Common viral replicons currently used include those based on alphaviruses such as Venezuelan Equine Encephalitis virus (VEEV), Sindbis virus (SINV) and Semliki Forest virus (SFV). They also share some favorable features of mRNA- based vaccines including modular design and Good Manufacturing Practice (GMP) compliant cell-free synthesis method. Preliminary in vitro studies have shown unmodified saRNAs outperform unmodified and modified standard mRNAs in antigen expression when delivered in lipid nanoparticle (LNP) formulations (Ramos da Silva et al. , 2023). Despite the therapeutic potential of saRNAs, there are several roadblocks to overcome. saRNAs are much larger than mRNAs, 9-12 kb in length, and mimic viral infection as demonstrated when saRNA-transfected cells show interferon (IFN) being triggered by dsRNA intermediates, and cellular host antiviral response leading to antigen-specific B and T cell responses. The innate immune response is activated by pattern recognition receptors (PRR) that detect replicon-generated pathogen-associated molecular patterns (PAMPs) on nucleic acids. Apart from the host innate immune response, dendritic cell expressed PRR detection of saRNAs lead to the activation of adaptive immune responses potentially restricting saRNA and antigen expression (Tan et al., 2023).
[0010] Thus, there is a need for novel saRNAs that are able to express a heterologous antigen at high efficiency while at the same time having a better safety profile.
[0011] SUMMARY OF THE INVENTION
[0012] The present invention relates to the construction of a novel saRNA utilizing the rubella virus replicon (i.e., the RuV RA27 / 3 vaccine strain) as an alternative virus-derived replicon that demonstrates effective expression of a desired antigen. Having derived from a commonly used vaccine, it has a better safety profile with reduced risk of adverse events compared to the current alphavirus-derived saRNAs. This novel RuV-based saRNA replicon can be used as a vaccine vector or in cancer therapy.
[0013] Thus, in a first aspect of the invention, there is provided a Rubivirus-based self-amplifying RNA (saRNA) comprising:
[0014] (i) a first polynucleotide comprising a 5’-untranslated region (5’-UTR) of the Rubivirus;
[0015] (ii) a second polynucleotide encoding a full length p200 polypeptide of the Rubivirus;
[0016] (iii) a third polynucleotide comprising a subgenomic promoter of the Rubivirus;
[0017] (iv) a fourth polynucleotide encoding a full length capsid protein of the Rubivirus;
[0018] (v) a fifth polynucleotide encoding at least the first 10 amino acids of the E2 protein of the Rubivirus;
[0019] (vi) a sixth polynucleotide encoding a first protein of interest;
[0020] (vii) a seventh polynucleotide comprising at least the last 53 nucleotides of the E1 coding sequence of the Rubivirus; and
[0021] (viii) an eighth polynucleotide comprising a 3’-UTR of the Rubivirus.
[0022] In some embodiments, the Rubivirus is a Rubella virus (RuV), a Ruhugu virus (RuhV) or a Rustrela virus (RusV). Preferably, the Rubivirus is a RuV selected from a group consisting of RA 27 / 3 strain, HPV77 / DE5 strain, Cendehill strain, M33 strain, Therien strain, Thomas strain and IB2 strain.
[0023] In some embodiments, the first polynucleotide comprises a 40nt 5’-UTR of the Rubivirus.
[0024] In some embodiments, the first polynucleotide comprises, or consists of, the nucleotide sequence set forth in SEQ ID NO: 22.
[0025] In some embodiments, the p200 polypeptide comprises a non-mutated RNA dependent RNA polymerase (RdRP) catalytic motif. Preferably, the p200 consists of an amino acid sequence set forth in SEQ ID NO: 2. More preferably, the second polynucleotide comprises, or consists of, the nucleotide sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 12.
[0026] In some embodiments, the subgenomic promoter comprises, or consists of, the nucleotide sequence set forth in SEQ ID NO: 24.
[0027] In some embodiments, the full length capsid consists of the amino acid sequence set forth in SEQ ID NO: 4. Preferably, the fourth polynucleotide comprises, or consists of, the nucleotide sequence set forth in SEQ ID NO: 5.
[0028] In some embodiments, the first 10 amino acids of the E2 protein has an amino acid sequence set forth in SEQ ID NO: 6. Preferably, the fifth polynucleotide comprises, or consists of, the nucleotide sequence set forth in SEQ ID NO: 7.
[0029] In some embodiments, the seventh polynucleotide comprises, or consists of, the nucleotide sequence set forth in SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 or SEQ ID NO: 17.
[0030] In some embodiments, the eighth polynucleotide comprises, or consists of, the nucleotide sequence set forth in SEQ ID NO: 19.
[0031] In some embodiments, the saRNA according to the present invention further comprises a 5’- cap, a 3’-poly A tail, and / or a polynucleotide encoding a hepatitis delta virus ribozyme (HDVr).
[0032] In some embodiments, the 5’-cap is a non-modified cap m7GpppNp, a CleanCap rn7GpppAmU, or a CleanCap rn7GpppAmG. In some embodiments, the saRNA may further comprise ninth polynucleotide encoding a second protein of interest.
[0033] In some embodiments, the protein of interest is a reporter protein or an antigen. Preferably, the antigen is a virus antigen, a bacteria antigen or a tumor antigen.
[0034] In a second aspect of the invention, there is provided a vector comprising a polynucleotide molecule encoding the saRNA according to the present invention.
[0035] In a third aspect of the invention, there is provided a trans-amplifying RNA (taRNA) system based on Rubivirus comprising:
[0036] (a) a saRNA and a non-replicating RNA (nrRNA), wherein the saRNA comprises 5’-UTR of the Rubivirus, a polynucleotide comprising a subgenomic promoter of the Rubivirus, a polynucleotide encoding a full length capsid of the Rubivirus, a polynucleotide encoding at least the first 10 amino acids of E2 protein of the Rubivirus, a polynucleotide encoding a protein of interest, a polynucleotide comprising the last 53 nucleotides of E1 protein of the Rubivirus, and a polynucleotide comprising 3’-UTR of the Rubivirus, the nrRNA comprises a polynucleotide encoding a full length p200 polypeptide of the Rubivirus which provides a RNA dependent RNA Polymerase, or
[0037] (b) a saRNA and a nrRNA, wherein the saRNA comprises 5’-UTR of the Rubivirus, a polynucleotide comprising a subgenomic promoter of the Rubivirus, a polynucleotide encoding a protein of interest, a polynucleotide comprising the last 53 nucleotides of E1 protein of the Rubivirus, and a polynucleotide comprising 3’-UTR of the Rubivirus, and the nrRNA comprises a polynucleotide encoding a full length p200 polypeptide of the Rubivirus which provides a RNA dependent RNA Polymerase and a polynucleotide encoding a full length capsid of the Rubivirus, or
[0038] (c) two saRNAs, wherein each saRNA comprises 5’-UTR of the Rubivirus, a polynucleotide encoding a full length p200 polypeptide of the Rubivirus which provides a RNA dependent RNA Polymerase, a polynucleotide comprising a subgenomic promoter of the Rubivirus, a polynucleotide encoding a full length capsid of the Rubivirus, a polynucleotide encoding at least the first 10 amino acids of E2 protein of the Rubivirus, a polynucleotide comprising the last 53 nucleotides of E1 protein of the Rubivirus, and a polynucleotide comprising 3’-UTR of the Rubivirus, wherein one saRNA further comprises a polynucleotide encoding a protein of interest. The 5’-UTR, p200 polypeptide, subgenomic promoter, capsid, the first 10 amino acids of E2 protein, the last 53 nucleotides of E1 protein and 3’-UTR of the Rubivirus of the taRNA system have the same meaning as those defined in the first aspect of the invention.
[0039] In some embodiments, the saRNA and nrRNA in the above (a) and (b), or the two saRNAs in the above (c) may be encoded by separate vectors.
[0040] In a fourth aspect of the invention, there is provided a composition comprising the saRNA according to the first aspect of the present invention, or the vector according to the second aspect of the present invention, or the taRNA system according to the third aspect of the present invention, and a pharmaceutically acceptable carrier.
[0041] In some embodiments, the saRNA is encapsulated in, bound to, or adsorbed on any one of a cationic lipid, a liposome, a lipid nanoparticle (LNP), a polyplex, a cochleate, a virosome, an immune-stimulating complex, a Red blood cell-derived extracellular vesicle (RBCEV), a microparticle, a microsphere, a nanosphere, a unilamellar vesicle, a multilamellar vesicle, an oil-in-water emulsion, a water-in-oil emulsion, an emulsome, a polycationic peptide, and a cationic nanoemulsion, or a combination thereof. Preferably, the saRNA is encapsulated in a LNP or a RBCEV.
[0042] In some embodiments, the composition is a prophylactic or a therapeutic vaccine. Preferably, the therapeutic vaccine is for treatment of cancer.
[0043] In a fifth aspect of the invention, there is provided a method for inducing an immune response in a subject, comprising administering an effective amount of the saRNA according to the first aspect of the present invention, or the vector according to the second aspect of the present invention, or the taRNA system according to the third aspect of the present invention, or the composition according to the fourth aspect of the present invention to the subject.
[0044] In some embodiments, the protein of interest is a virus or bacteria antigen. Preferably, the virus antigen is selected from a group consisting of a SARS-CoV-2 antigen, a Hepatitis B virus (HBV) antigen, an influenza virus hemagglutinin (HA) antigen, a Varicella-Zoster Virus (VZV) antigen, a SARS-CoV-1 antigen, a Middle East Respiratory Syndrome (MERS) coronavirus antigen, an Epstein-Barr virus (EBV) antigen, a herpes simplex virus (HSV) antigen, a rabies virus antigen, a cytomegalovirus (CMV) antigen, a human immunodeficiency virus (HIV) antigen, a Zika virus antigen, a respiratory syncytial virus (RSV) antigen, and a human papillomavirus (HPV) antigen. Preferably, the bacteria antigen is selected from a group consisting of a Mycobacterium tuberculosis antigen, a Chlamydia trachomatis antigen, a Staphylococcus aureus antigen, a Streptococcus pneumonia antigen, a Neisseria meningitidis antigen, a Clostridium tetani antigen, and a Corynebacterium diphtheriae antigen.
[0045] In a sixth aspect of the invention, there is provided a method for treating a cancer in a subject, comprising administering an effective amount of the saRNA according to the first aspect of the present invention, or the vector according to the second aspect of the present invention, or the taRNA system according to the third aspect of the present invention, or the composition according to the fourth aspect of the present invention to the subject.
[0046] In some embodiments, the protein of interest is a tumor antigen selected from the group ovalbumin, Wilms’ tumor 1 (WT1), Mucin 1, human epidermal growth factor receptor (HER2) and Prostate acid phosphatase (PAP) protein.
[0047] BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Certain embodiments of the present disclosure are described more fully hereinafter with reference to the accompanying drawings.
[0049] Figure 1 shows a schematic diagram of the self-amplifying RNA (saRNA) and conventional mRNA vaccine constructs. (A) Diagram of conventional mRNA vaccine construct. (B) A bridged general view of saRNA vaccine construct. Non-structural proteins 1-4 (nsPs) encode RNA-dependent RNA polymerase for producing negative genomic RNA, which then serves as template for genomic RNA and subgenomic RNA synthesis. Many copies of subgenomic RNA are produced which leads to more translation of the antigen compared to conventional mRNA vaccine.
[0050] Figure 2 shows the design of a new RuV based saRNA according to the invention. (A) Schematic paradigm of RuV RA27 / 3 strain genome. Numbers at the bottom indicate the numbering of amino acids in each ORF. m7G represents the cap. (B) A plasmid encoding a new RuV based saRNA replicon WT containing full length p200 and capsid (CFL), the first 10 amino acids of E2 (E2i-io), Gaussia luciferase reporter followed by 2A sequence, and the last 173 amino acids of E1 (EI309-481). (C) The RNA-dependent RNA Polymerases (RdRP) catalytic active site GDD of WT were mutated into GAA, to create a catalytically inactive mutant. (D) Luciferase activities of WT and GAA saRNA replicons measured in BHK21 cells. BHK-21 cells were plated in 24-well plate and transfected with WT and GAA mutant saRNA replicon at a concentration of 300 ng / well when the cell confluency reached 70%. Supernatant was harvested at different time points and measured for luciferase activity. For (B) and (C), the arrow represents the T7 promoter, and HDVr encodes for hepatitis delta virus ribozyme (HDVr) sequence. The three black lines from left to right represent polynucleotides encoding the 5’- UTR, the subgenomic promoter and 3’-UTR respectively.
[0051] Figure 3 shows p200 codon optimization of the RuV saRNA replicon. (A) Overview of WT, p200 codon optimization (p200-0pti) and p200 codon optimization and further deletion of capsid (p200-Gpti-AC) saRNA replicons. Optimized sequences are indicated in gray. The three black lines from left to right represent 5’-UTR, the subgenomic promoter and 3’-UTR respectively. (B) Luciferase activities of WT, GAA mutant, p200-0pti and p200-Gpti-AC saRNA replicons. For (B), BHK21 cells in 6-well plate were transfected with various saRNA replicons at a concentration of 1 pg / well when the cell confluency reached 70%. Supernatant was harvested at different time points and measured for luciferase activity.
[0052] Figure 4 shows RuV saRNA replicons with various truncated E2. (A) The capsid structure model predicted by AlphaFold2. (B) The structures of saRNA replicons with different version of truncated E2. AC is complete deletion of the capsid, AC35-270 is deletion of 35-270 amino acids of the capsid, and the same applies to AC53-270, AC89-270, and AC113-270. Kozak sequence (represented by star) was included in the AC replicon as the translation initiation site. The three black lines from left to right represent 5’-UTR, the subgenomic promoter and 3’-UTR respectively. (C) Luciferase activities of capsid truncated saRNA replicons measured in BHK21 cells. BHK-21 cells were plated in 24-well plate and transfected with WT and GAA mutant saRNA replicon at a concentration of 300 ng / well when the cell confluency reached 70%.
[0053] Figure 5 shows RuV saRNA replicons with various truncated E1. (A) Predicted secondary structure of 3’ terminus of the WT saRNA (305 nucleotides) containing the last 246 nucleotides of E1 and 59 nucleotides of 3’-UTR. (B) The structures of saRNA replicons with different version of truncated E1. Red star represents stop codon. 3’-305 means the replicon maintains the last 305 nucleotides (including the last 246 nucleotides of E1 and the original 59 nucleotides of 3’-UTR) at the 3’ terminus, and the same applies to other replicons. The three black lines from left to right represent 5’-UTR, the subgenomic promoter and 3’-UTR respectively. (C) Luciferase activities of 3’-305, 3’-250 and 3’-59 replicons measured in BHK21 cells up to 96 hours after transfection. (D) Luciferase activities of 3’-305, 3’-250, 3’-215, 3’- 132, 3’-112 and 3’-94 measured in BHK21 cells up to 6 days after transfection. For (C) and (D), BHK21 cells in 24-well plate were transfected with saRNA replicons at a concentration of 300 ng / well when the cell confluency reached 70%. Supernatant was harvested at different time points and measured for luciferase activity. Figure 6 shows RuV saRNA replicons with different cap structures. (A) Luciferase activities of saRNA replicons with different cap structures compared with WT and GAA mutant measured in BHK21 cells. (A) Luciferase activities of saRNA replicons with different cap structures compared with WT and GAA mutant measured in Vero cells. Cells in 24-well plate were transfected with saRNA replicons at a concentration of 300 ng / well when the cell confluency reached 70%. Supernatant was harvested at different time points and measured for luciferase activity.
[0054] Figure 7 shows comparison between RuV saRNA according to the invention and VEEV SaRNA. (A) Overview of saRNA formulation and detection of luciferase activity in DC2.4 cells. (B-C) Luciferase activity in DC2.4 cells at 24 hours (B) and 48 hours (C) after transfection respectively. (D-F) Relative mRNA expression of lfn-p (D), lfn-a (E) and Tnf-a (F) normalized to GAPDH. (G) Light microscopy of DC2.4 cells post infected with RuV and VEEV SaRNA replicons compared to the untreated at 48 hours. UT: untreated DC2.4 cells.
[0055] Figure 8 shows bioluminescent activities of BALB / c nude mice injected with different saRNA replicons (n=2 for each group) up to 13 days post injection.
[0056] Figure 9 shows the activity of the taRNA system. (A) Schematic diagram of co-transfection. (B) Luciferase activities of BHK21 cells transfected with the combination of two vectors GAA +3’-250 mcherry (i.e., the taRNA system) compared with those transfected with one vector alone.
[0057] DETAILED DESCRIPTION OF THE INVENTION
[0058] Further details of the invention will now be described with reference to the following nonlimiting examples. Unless otherwise defined herein, technical and scientific terms used in the present description have the meanings that are commonly understood by those of ordinary skill in the art.
[0059] A. Definitions
[0060] As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
[0061] As used herein, the term “comprising” may include the embodiments “consisting of” and “consisting essentially of”. The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases that require the presence of the named ingredients / steps and permit the presence of other ingredients / steps. However, such description should be construed as also describing compositions, mixtures, or processes as “consisting of” and “consisting essentially of” the enumerated ingredients / steps, which allows the presence of only the named ingredients / steps, along with any impurities that might result therefrom, and excludes other ingredients / steps.
[0062] As used herein, the term “subject” refers to animals, typically mammalian animals. Any suitable mammal can be treated by a method described herein. Non-limiting examples of mammals include humans, non-human primates (e.g., apes, gibbons, chimpanzees, orangutans, monkeys, macaques, and the like), domestic animals (e.g., dogs and cats), farm animals (e.g., horses, cows, goats, sheep, pigs) and experimental animals (e.g., mouse, rat, rabbit, guinea pig). In some embodiments, a mammal is a human. A mammal can be any age or at any stage of development (e.g., an adult, teen, child, infant, or a mammal in utero). A mammal can be male or female. In some embodiments, a subject is a human. In some embodiments, a subject has or is diagnosed of having a particular disease, for example, non- tuberculous mycobacteria infection.
[0063] As used herein, the terms “saRNA,” “self-amplifying RNA” and “replicon” may be used interchangeably, and refer to RNA with the ability to replicate itself. Self-amplifying RNA molecules may be produced by using replication elements derived from a virus or viruses, e.g., alphaviruses, rubiviruses, and substituting the structural viral polypeptides with a nucleotide sequence encoding a polypeptide of interest. A self-amplifying RNA molecule is typically a positive-strand molecule that may be directly translated after delivery to a cell, and this translation provides an RNA-dependent RNA polymerase which then produces both antisense and sense transcripts from the delivered RNA. The delivered RNA leads to the production of multiple daughter RNAs. These daughter RNAs, as well as collinear subgenomic transcripts, may be translated themselves to provide in situ expression of an encoded gene of interest, such as an antigen or a reporter protein, or may be transcribed to provide further transcripts with the same sense as the delivered RNA which are translated to provide in situ expression of the protein of interest, e.g., an antigen. The overall result of this sequence of transcriptions is an amplification in the number of the introduced saRNAs and so the encoded gene of interest, e.g., an antigen, can become a major polypeptide product of the cells.
[0064] As used herein, the term “promoter” as used herein refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. As used herein, the term “operably linked” as used herein refers to a first molecule that can be joined to a second molecule, wherein the molecules are so arranged that the first molecule affects the function of the second molecule. The term “operably linked” includes the juxtaposition of two or more components (e.g., a promoter and another sequence) such that both components function normally and allow for the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components. The two molecules may or may not be part of a single contiguous molecule and may or may not be adjacent. For example, a promoter is operably linked to a transcribable polynucleotide molecule if the promoter modulates transcription of the transcribable polynucleotide molecule of interest in a cell. In additional embodiments, two portions of a transcription regulatory element are operably linked to one another if they are joined such that the transcriptionactivating functionality of one portion is not adversely affected by the presence of the other portion. Two transcription regulatory elements may be operably linked to one another by way of a linker nucleic acid (e.g., an intervening non-coding nucleic acid) or may be operably linked to one another with no intervening nucleotides present.
[0065] As used herein, the term “poly A tail” refers to a stretch of consecutive adenine residues, which may be attached to the 3'end of the RNA molecule. The poly-A tail may increase the half-life of the RNA molecule.
[0066] B. Rubivirus based saRNA
[0067] The Rubivirus genus in the Matonaviridae family now has three members, Rubella virus (RuV), Ruhugu virus (RuhV) and Rustrela virus (RusV). They are enveloped viruses with a singlestranded positive-sense RNA genome. It is reported that the genome organizations of RuV, RuhV and RusV are identical, consisting of 5’-UTR, a first big open reading frame (ORF) encoding non-structural polyproteins p200 (which is autocleaved to form p150 and p90 proteins), an intergenic region, a second big ORF encoding structural polyproteins capsid, E2 and E1 , and 3’-UTR. RuhV shows very high similarity to RuV in each of the five mature polypeptides of the protein-coding viral genome, while the nucleotide sequences of RusV are 97.4 to 100% similar to RuV within p90 and E1 coding regions. The modelled tertiary and quaternary structures of trimeric RuhV and RusV E1 are homologous to RuV E1. B-cell epitopes within the E1 of RuV, RuhV and RusV are highly conserved.
[0068] Rubella virus (RuV) is the pathogenic agent of the disease rubella, transmitted only between humans via the respiratory route. An effective rubella vaccine currently used is based on the RuV RA27 / 3 strain, which is a live-attenuated vaccine. This vaccine is also part of routine childhood immunization schedules as measles, mumps rubella vaccine (MMR). It presents high immunogenicity, generates long-term immunity after a single dose, and effectively prevents clinical disease with very low risk of adverse effects.
[0069] Thus, the present invention provides a Rubivirus based saRNA comprising:
[0070] (i) a first polynucleotide comprising a 5’-untranslated region (5’-UTR) of the Rubivirus;
[0071] (ii) a second polynucleotide encoding a full length p200 polypeptide of the Rubivirus;
[0072] (iii) a third polynucleotide comprising a subgenomic promoter of the Rubivirus;
[0073] (iv) a fourth polynucleotide encoding a full length capsid protein of the Rubivirus;
[0074] (v) a fifth polynucleotide encoding at least the first 10 amino acids of the E2 protein of the Rubivirus;
[0075] (vi) a sixth polynucleotide encoding a first protein of interest;
[0076] (vii) a seventh polynucleotide comprising at least the last 53 nucleotides of the E1 coding sequence of the Rubivirus; and
[0077] (viii) an eighth polynucleotide comprising a 3’-UTR of the Rubivirus.
[0078] The present invention also provides a vector comprising a polynucleotide molecular encoding the saRNA of the present invention.
[0079] In some embodiments, the Rubivirus is a Rubella virus (RuV), a Ruhugu virus (RuhV) or a Rustrela virus (RusV). In some embodiments, the RuV may be any strain known in the art. For example, the RuV may be selected from a group consisting of RA 27 / 3 strain, HPV77 / DE5 strain, Cendehill strain, M33 strain, Therien strain, Thomas strain and IB2 strain.
[0080] P200 is a polyprotein precursor, and it is translated from the first ORF of the RuV genomic RNA and undergoes cis cleavage to produce two non-structural proteins, p150 and p90. Amino acid sequence analysis has revealed global amino acid motifs indicative of RNA- dependent RNA polymerase (replicase), helicase, methyltransferase, and proteinase activities. In addition, a short region of unknown function, termed the X motif, is found within p150 and is also present in the alphavirus nsP3 protein and the hepatitis E virus 5’ ORF product. The amino acid motifs for proteinase and methyltransferase are located in the carboxy terminus of p150, while the motifs for the replicase (GDD) and the helicase (GxGKT and DExx) are located in the carboxy terminus of p90. Thus, the RuV gene order for the first ORF is 5’- methyltransferase-X-protease-helicase-replicase-3’. In some embodiments, the p200 polypeptide is non-mutated, and thus comprising an RNA- dependent RNA polymerase (RdRP) catalytic motif GDD. Preferably, the p200 consists of an amino acid sequence set forth in SEQ ID NO: 2. More preferably, the second polynucleotide is a wild type p200 coding sequence (i.e., that is not codon optimized). Preferably, the second polynucleotide comprises, or consists of, a nucleotide sequence set forth in SEQ ID NO: 3.
[0081] The RuV capsid protein is a non-glycosylated, phosphorylated, disulfide-linked homodimer consisting of 300 amino acid residues. It contains clusters of proline and arginine residues, which have been postulated to be involved in binding to the RV genomic RNA to form the viral nucleocapsids. In some embodiments, the full length capsid consists of an amino acid sequence set forth in SEQ ID NO: 4. Preferably, the fourth polynucleotide comprises, or consists of, a nucleotide sequence set forth in SEQ ID NO: 5.
[0082] The virion envelope proteins, E1 and E2, are type 1 membrane glycoproteins observed as spikes in the form of E1-E2 heterodimers on the virion surface. Using monoclonal antibodies, it has been shown that the E1 protein contains at least six non-overlapping epitopes, some of which are associated with hemagglutination and neutralization. E1 appears to be the main surface protein, with domains involved in the attachment of the virus to the cell. The first 10 amino acids of E1 act as a signal peptide, mediating the cleavage between capsid and E2 protein. E2 is disulfide-linked to E1 in the mature virion and is poorly exposed. However, E2 does contain partial hemagglutination and neutralizing epitopes and may also carry strainspecific epitopes.
[0083] In some embodiments, the first 10 amino acids of the E2 protein consists of an amino acid sequence set forth in SEQ ID NO: 6. Preferably, the fifth polynucleotide comprises, or consists of, a nucleotide sequence set forth in SEQ ID NO: 7.
[0084] In some embodiments, the seventh polynucleotide comprises, or consists of, the last 53 nucleotides (SEQ ID NO 17), the last 73 nucleotides (SEQ ID NO 16), the last 156 nucleotides (SEQ ID NO 15), the last 191 nucleotides (SEQ ID NO 14), the last 246 nucleotides (SEQ ID NO 13), or the last 519 nucleotides (SEQ ID NO 11) of the E1 coding sequence of the RuV
[0085] The 5'untranslated region (UTR) is a regulatory region situated upstream of the 5' end of a protein coding sequence. 5'UTRs may contain various regulatory elements, e.g., stem-loop structure, and an internal ribosome entry site (IRES), which may play a role in the control of translation initiation. The 3'UTR, situated downstream of a protein coding sequence, may be involved in regulatory processes including transcript cleavage, stability and polyadenylation, translation, and mRNA localizationin some embodiments, the UTR increases protein synthesis. In some embodiments, the 5' UTR and the 3'UTR are derived from a Rubivirus, such as Rubella virus (RuV), Ruhugu virus (RuhV) or Rustrela virus (RusV), preferably RuV. In some embodiments, the 5’-UTR comprises, or consists of, a nucleotide sequence set forth in SEQ ID NO: 22. In some embodiments, the 3’-UTR comprises, or consists of, a nucleotide sequence set forth in SEQ ID NO: 19.
[0086] In some embodiments, the polynucleotide molecule according to the present invention may further comprise a 5’-cap, a 3’-poly A tail coding sequence, and / or a polynucleotide encoding a hepatitis delta virus ribozyme (HDVr).
[0087] In some embodiments, the saRNA of the present invention includes a 5'-cap. In some embodiments, the 5'-cap moiety is a natural 5'-cap. A “natural 5'-cap” is defined as a cap that includes 7-methylguanosine (m7G) connected to the 5' end of an mRNA molecule through a 5'to 5' triphosphate linkage. Different viruses may have different caps. Wild-type RuV has a cap of m7GpppNp (cap-0). In some embodiments, the cap is a non-modified cap, a CleanCap m7GpppAmU, or a CleanCap m7GpppAmG.
[0088] In some embodiments, the saRNA of the present invention further includes a poly A tail coding sequence. Poly-A tails may play key regulatory roles in enhancing translation efficiency and regulating the efficiency of mRNA quality control and degradation. In some embodiments, the poly A tail includes 5-400 nucleotides in length. The poly A tail nucleotide length may be equal to any one of, at least any one of, at most any one of, or between any two of 5, 6, 7, 8, 9, 10, 15, 20, 25. 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, and 400. In some embodiments, the RNA molecule includes a poly A tail that includes about 25 to about 400 adenosine nucleotides, a sequence of about 50 to about 400 adenosine nucleotides, a sequence of about 50 to about 300 adenosine nucleotides, a sequence of about 50 to about 250 adenosine nucleotides, a sequence of about 60 to about 250 adenosine nucleotides, or a sequence of about 40 to about 100 adenosine nucleotides. In some embodiments, the RNA molecule includes a poly A tail includes a sequence of greater than 30 adenosine nucleotides (“As”). In some embodiments, the RNA molecule includes a poly A tail that includes about 55 As. In some embodiments, the saRNA of the present invention further includes a polynucleotide encoding a hepatitis delta virus ribozyme (HDVr). The ribozyme acts to process the RNA transcripts to unit lengths in a self-cleavage reaction during replication of the virus. It is active in vivo in the absence of any protein factors and was the fastest known naturally occurring self-cleaving RNA at the time of its discovery. In some embodiments, the HDVr consists of an amino acid sequence set forth in SEQ ID NO: 23.
[0089] In some embodiments, the saRNA may encode more than one (such as 2, 3, 4, 5, 6, 7 or more) protein of interest. Thus, in one embodiment, the polynucleotide molecule may further comprise an eighth polynucleotide encoding a second protein of interest. In some embodiments, the protein of interest is a reporter protein or an antigen.
[0090] In some embodiments, the protein of interest is a reporter protein. As used herein, the term “reporter protein” refers to a protein that confers organisms expressing it easily identified and measured characteristics. Reporter proteins can be used to track the physical location of a target protein or to monitor gene expression level of the target protein. There are generally two types of reporter protein, non-fluorescent type (e.g., an enzyme) and fluorescent type. Chloramphenicol acetyltransferase (CAT), Cre recombinase (Cre), luciferase (such as Gaussia luciferase) and lacZ are commonly employed as non-fluorescent reporter proteins. Examples of fluorescent reporter proteins are green fluorescent protein (GFP) and red fluorescent protein (RFP) as well as their variants, such as yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), enhanced yellow fluorescent protein (EYFP), enhanced cyan fluorescent protein (ECFP), enhanced green fluorescent protein (EGFP), monomeric cherry (mCherry) and tandem dimer Tomato (tdTomato), and Lucigen Yellow (LucY). In some embodiments, the combination of non-fluorescent reporter coding genes with fluorescent protein-coding genes into a single sequence are used to provide an additional tool for analyzing cell populations in vivo and ex vivo, because this strategy allows 2 signals to be monitored independently. In some embodiments, the reporter protein may be selected from a group consisting of CAT, Cre, luciferase, lacZ, GFP, RFP, YFP, CFP, EYFP, ECFP, EGFP, mCherry, tdTamato and LucY.
[0091] In some embodiments, the protein of interest is an antigen, such as a virus antigen, a bacteria antigen, or a tumor antigen. As used herein, the term “antigen” refers to a molecule that may be recognized by the immune system and trigger an immune response by activating leukocytes in a subject. Some vaccines currently used (such as mRNA vaccines) are developed by expressing a foreign antigen to enhance the production of antigen-specific antibodies. Examples of virus antigens that may be used in the present invention include but are not limited to SARS-CoV-2 antigens (such as the Spike protein or the receptor-binding domain (RBD) thereof, and the NSP3 protein), Hepatitis B virus (HBV) antigens (such as surface antigen HBsAg), influenza virus hemagglutinin (HA) antigens (such as H1 , H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, or H18), Varicella-Zoster Virus (VZV) antigens (such as a glycoprotein E (gE) antigen, a glycoprotein B (gB) antigen, a glycoprotein H (gH) antigen, a glycoprotein L (gl_) antigen, a glycoprotein N (gN) antigen, a glycoprotein I (gl) antigen), SARS-CoV-1 antigens (such as the Spike protein), Middle East Respiratory Syndrome (MERS) coronavirus antigens (such as the Spike protein), Epstein-Barr virus (EBV) antigens (such as nuclear antigen 1 , latetn membrane protein (LMP)1 and LMP2, envelope proteins), herpes simplex virus (HSV) antigens (such as HSV1 or HSV2), rabies virus antigens (such as a nucleoprotein (N), a phosphoprotein (P), a matrix protein (M), a glycoprotein (G) or a polymerase (L) antigen), cytomegalovirus (CMV, human betaherpesvirus 5) antigens (such as the glycoprotein B thereof), human immunodeficiency virus (HIV) antigens (such as p24 and Nef protein thereof), Zika virus antigen (such as NS1 protein or envelope protein), respiratory syncytial virus (RSV) antigens (such as RSV glycoprotein RSV-G, or RSV fusion glycoprotein RSV-F), human papillomavirus (HPV) antigens (such as E6 protein, E7 protein, L1 protein, L2 protein).
[0092] Examples of bacteria antigens that may be used in the present invention include but are not limited to Mycobacterium tuberculosis antigens (such as H37Rv, malate synthase or MPT51), Chlamydia trachomatis antigens (such as an outer membrane protein antigen), Staphylococcus aureus antigens, Streptococcus pneumonia antigens (such as polysaccharides), Neisseria meningitidis antigens (such as polysaccharides), Clostridium tetani antigens (such as polysaccharide or conjugates thereof), Corynebacterium diphtheriae antigens (such as polysaccharide or conjugates thereof).
[0093] In some embodiments, the protein of interest is a tumor antigen. As used herein, the term “tumor antigen” refers to an antigenic substance produced in tumor cells. Examples of tumor antigen that may be used in the present invention include but not limited to ovalbumin, Wilms’ tumor 1 (WT1), Mucin 1 , human epidermal growth factor receptor 2 (HER2), Prostate acid phosphatase (PAP) protein.
[0094] In some embodiments, the saRNA of the present invention may comprise one or more sub- genomic promoters to direct expression of the heterologous sequence (e.g., gene of interest) operably linked to said promoters. For example, the sub-genomic promoter may be derived from a Rubivirus, preferably RuV.
[0095] The present invention further provides a trans amplifying RNA (taRNA) system based on Rubivirus comprising:
[0096] (a) a saRNA and a non-replicating RNA (nrRNA), wherein the saRNA comprises 5’-UTR of the Rubivirus, a polynucleotide comprising a subgenomic promoter of the Rubivirus, a polynucleotide encoding a full length capsid of the Rubivirus, a polynucleotide encoding at least the first 10 amino acids of E2 protein of the Rubivirus, a polynucleotide encoding a protein of interest, a polynucleotide comprising the last 53 nucleotides of E1 protein of the Rubivirus, and a polynucleotide comprising 3’-UTR of the Rubivirus, the nrRNA comprises a polynucleotide encoding a full length p200 polypeptide of the Rubivirus which provides a RNA dependent RNA Polymerase, or
[0097] (b) a saRNA and a nrRNA, wherein the saRNA comprises 5’-UTR of the Rubivirus, a polynucleotide comprising a subgenomic promoter of the Rubivirus, a polynucleotide encoding a protein of interest, a polynucleotide comprising the last 53 nucleotides of E1 protein of the Rubivirus, and a polynucleotide comprising 3’-UTR of the Rubivirus, and the nrRNA comprises a polynucleotide encoding a full length p200 polypeptide of the Rubivirus which provides a RNA dependent RNA Polymerase and a polynucleotide encoding a full length capsid of the Rubivirus, or
[0098] (c) two saRNAs, wherein each saRNA comprises 5’-UTR of the Rubivirus, a polynucleotide encoding a full length p200 polypeptide of the Rubivirus which provides a RNA dependent RNA Polymerase, a polynucleotide comprising a subgenomic promoter of the Rubivirus, a polynucleotide encoding a full length capsid of the Rubivirus, a polynucleotide encoding at least the first 10 amino acids of E2 protein of the Rubivirus, a polynucleotide comprising the last 53 nucleotides of E1 protein of the Rubivirus, and a polynucleotide comprising 3’-UTR of the Rubivirus, wherein one saRNA further comprises a polynucleotide encoding a protein of interest.
[0099] In some embodiments, the saRNA and nrRNA in the above (a) and (b) or the two saRNAs in the above (c) are encoded by separate vectors.
[0100] The saRNA of the invention may be made using a DNA plasmid as a template. RNA copies may then be made by in vitro transcription using a polymerase, such as T7 polymerase. It will be appreciated that other RNA polymerases could be used instead of T7 polymerase, for example the SP6 or the T3 polymerase, in which case the saRNA construct may comprise the SP6 or T3 promoter instead. The vector of the second aspect encoding the RNA construct of the first aspect may for example be a plasmid, cosmid or phage and / or be a viral vector. Such recombinant vectors are highly useful in the delivery systems of the invention for transforming cells with the nucleotide sequences. The nucleotide sequences may preferably be a DNA sequence, and it is this DNA sequence which encodes the RNA sequence forming the saRNA of the first aspect.
[0101] C. Composition comprising saNRA and taRNA system
[0102] The present invention also provides a composition comprising the saRNA according to the first aspect of present invention, or the vector according to the second aspect of present invention, or the taRNA system according to the third aspect of present invention, and a pharmaceutically acceptable carrier.
[0103] In some embodiments, the composition further includes a lipid-based delivery system, which delivers an RNA or DNA molecule to the interior of a cell, where it can then replicate and / or express the encoded polypeptide of interest. The delivery system may have adjuvant effects which enhance the immunogenicity of an encoded antigen. In some embodiments, the composition further includes neutral lipids, cationic lipids, cholesterol, and polyethylene glycol (PEG), and forms nanoparticles that encompass the RNA or DNA molecules. In some embodiments, the composition further includes any one of a cationic lipid, a liposome, a lipid nanoparticle, a polyplex, a cochleate, a virosome, an immune-stimulating complex, a red blood cell-derived extracellular vesicle (RBCEV), a microparticle, a microsphere, a nanosphere, a unilamellar vesicle, a multilamellar vesicle, an oil-in-water emulsion, a water-in-oil emulsion, an emulsome, a polycationic peptide, and a cationic nanoemulsion. In some embodiments, the saRNA molecule is encapsulated in, bound to or adsorbed on any one of a cationic lipid, a liposome, a lipid nanoparticle, a polyplex, a cochleate, a virosome, an immune-stimulating complex, a red blood cell-derived extracellular vesicle (RBCEV), a microparticle, a microsphere, a nanosphere, a unilamellar vesicle, a multilamellar vesicle, an oil-in-water emulsion, a water-in-oil emulsion, an emulsome, a polycationic peptide, and a cationic nanoemulsion, or a combination thereof.
[0104] In some embodiments, the pharmaceutically acceptable carrier may comprise isotonic agents (such as sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride), stabilizers (such as methionine, albumin, lipoprotein and globulin), buffers (such as various salts of organic or inorganic acids, bases, or amino acids, and include various forms of citrate, phosphate, tartrate, succinate, adipate, maleate, lactate, acetate, bicarbonate, or carbonate ions. Preferable buffers for use in the present invention include sodium or potassium buffers, for example, sodium phosphate, potassium phosphate, sodium succinate and sodium citrate ), cryoprotectants (such as trehalose and lactose), bulking agents (such as mannitol, lactose, sucrose, dextran, trehalose, glycine, arginine) and / or preservatives (such as antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal). The pharmaceutically acceptable carrier may also be administered separately but concurrently with the vaccine composition of the present invention.
[0105] In some embodiments, the composition is a prophylactic or a therapeutic vaccine. Preferably, the therapeutic vaccine is for treatment of cancer.
[0106] D. Use of the saRNA and taRNA system
[0107] The saRNA and taRNA system of the present invention may find various applications depending on the protein of interest selected to be included in the saRNA. For example, if the protein of interest is a virus or a bacteria antigen, then the saRNA and taRNA system of the present invention may be used as a prophylactic vaccine. For example, cervical cancer is a type of cancer that can be caused by HPV subtypes 16 and 18 and prevented by a HPV vaccine. If the protein of interest is a tumor antigen, then the saRNA and taRNA system of the present invention may be used as a therapeutic vaccine. In some embodiments, the saNRA of the present invention may also be used as a therapeutic vaccine when the protein of interest is a virus or a bacteria antigen, as some cancers are caused by viral or bacterial infection. For example, Bacillus Calmette-Guerin (BCG) vaccine targeting non-pathogenic Mycobacterium bovis has been approved as a therapeutic vaccine for the treatment of high risk non-muscle- invasive bladder cancer (NMIBC). If the protein of interest is a reporter protein, then the saRNA and taRNA system of the present invention may be used to observe or detect the expression and distribution of target proteins in cells and tissues.
[0108] Thus, the present invention also provides a method for inducing an immune response in a subject, comprising administering an effective amount of the saRNA according to the first aspect of present invention, or the vector according to the second aspect of present invention, or the taRNA system according to the third aspect of present invention, or the composition according to the fourth aspect of present invention to the subject.
[0109] In the above embodiment wherein the saRNA or the taRNA system is used for inducing an immune response, the protein of interest is a virus or bacteria antigen, and the saRNA or the taRNA system acts as a prophylactic vaccine.
[0110] The present invention also provides a method for treating a disease in a subject, comprising administering an effective amount of the polynucleotide molecule according to the first aspect of present invention, or the vector according to the second aspect of present invention, or the taRNA system according to the third aspect of present invention, or the composition according to the fourth aspect of present invention to the subject.
[0111] In the above embodiment wherein the saRNA or the taRNA system is used for treating a disease (such as cancer), the protein of interest is a tumor antigen, and the saRNA or the taRNA system acts as a therapeutic vaccine.
[0112] It should be understood that any and all embodiments of the present disclosure can be combined with technical features in any other embodiment or multiple other embodiments to obtain additional embodiments under the premise of no conflict. The invention includes such combinations resulting in further embodiments.
[0113] EXAMPLES
[0114] The examples and exemplary embodiments below are intended to be purely exemplary of the invention and should therefore not be considered to limit the invention in any way.
[0115] Example 1. Materials and Methods
[0116] Cell culture and saRNA transfection
[0117] BHK-21 and Vero cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% Fetal Bovine Serum (Gibco) at 37°C and with 5% CO2. Before transfection, cells were seeded in various types of cell plates as required. When cells reach -70% confluency, a saRNA replicon was transfected into cells using a TransIT-mRNA Transfection Kit (MirusBio, cat# MIR2250) as per manufacturer’s instructions.
[0118] In vitro transcription
[0119] The linearized vector encoding saRNA template was digested with restriction enzyme followed by agarose gel purification. In vitro transcription of DNA template was performed with the mMESSAGE mMACHINE T7 Transcription Kit (Invitrogen, cat# AM1344) as per manufacturer’s instructions in a 20 pL reaction. The reaction mixture was incubated at 37°C for 3 h. TurboDNAse was subsequently added and further incubated for 15 min to digest the DNA template. Then, LiCI and nuclease-free water were added, and gently mixed before the reaction mixture was stored at -20°C for 2 hours or overnight. The reaction mixture was centrifuged at 14,000 rpm for 10 min at 4°C and supernatant was discarded. 1 mL 80% ethanol was added to wash followed by centrifugation at 14,000 rpm for 10 min at 4°C. Supernatant was removed and the RNA pellet was dried in a biosafety cabinet for 20 min. 20 pL nuclease free water was added to dissolve RNA and the concentration was measured on a spectrophotometer (ThermoFisher Scientific NanoDrop™ 2000 / 2000c Spectrophotometer). An aliquot of RNA was added to RNA loading buffer and incubated at 85°C for 5 min before being run on a 0.6% agarose gel to determine the length of the transcript.
[0120] Luciferase assay
[0121] After saRNA replicon encoding Gaussia luciferase was transfected into cells, 10 pL of supernatant was collected at various time points into Corning 96-well microplate (cat# 3880), then 50 pL QUANTI-LUC luciferase detection reagent containing coelenterazine substrate (Invivogen, cat# rep-qlc2) was gently added and the luciferase activity was measured immediately by using a Biotek Synergy H1 plate reader.
[0122] Cytokine analysis
[0123] Total RNA in DC2.4 cells were extracted by TRIZOL digestion after the saRNA transfection. A LunaScript Multiplex One-Step RT-PCR kit (NEB #1555) was used to detect the specific cytokine expression.
[0124] In vivo study in mice
[0125] RuV 3’-250 saRNA (10 pg / mouse) and VEEV saRNA (10 pg / mouse) replicons were fused with in vivo JetRNA (Polyplus #101000122) or RBCEVs and then injected intramuscularly into 6-8-week-old C57BL / 6 mice (n=2 per group). Luciferase expression was measured at days 1 , 4, 7, 10 and 13 post-inoculations by imaging the mice for bioluminescence.
[0126] RBCEV method for preparing saRNA
[0127] The RBCEVs were transfected with saRNA at a ratio of 50 pg:1 pg by using REG1 transfection reagent (Carmine Therapeutics, USA) according to the manufacturer's protocols.
[0128] Example 2. Preparation of a RuV based saRNA
[0129] The genome of RuV RA27 / 3 strain is shown in Figure 2A. It consists of two ORFs, wherein the first ORF encodes a precursor polypeptide called p200 (amino acid sequence set forth in SEQ ID NO: 2), and the second ORF encodes a polypeptide called p110 which is operably linked to a subgenomic promoter (SEQ ID NO: 24). The p200 precursor is autocleaved to form p150 (residues 1-1301) and p90 (residues 1302-2116) proteins respectively. The RdRP catalytic activity site motif GDD is located between amino acid residues 1966-1968. The p110 precursor is processed to produce three major structural proteins: capsid (residues 1-300, amino acid sequence set forth in SEQ ID NO: 4), E2 (residues 301-582, amino acid sequence set forth in SEQ ID NO: 20) and E1 (residues 583-1063, amino acid sequence set forth in SEQ ID NO: 21).
[0130] A plasmid encoding a new RuV based saRNA replicon according to the invention was constructed based on the RuV RA27 / 3 strain, and was named as WT (Figure 2B). The WT saRNA replicon comprises a 5’-UTR (SEQ ID NO: 22), a full length p200 (SEQ ID NO: 2) coding sequence (SEQ ID NO: 3), a subgenomic promoter (SEQ ID NO: 24), a full length capsid (CFL, SEQ ID NO: 4) coding sequence (SEQ ID NO: 5), a nucleotide sequence (SEQ ID NO: 7) encoding the first 10 amino acids of E2 (E2i-io, SEQ ID NO: 6), a Gaussia luciferase gene (as an example of gene of interest, SEQ ID NO: 9) followed by a F2A sequence, a nucleotide sequence (SEQ ID NO: 11) encoding the last 173 amino acids of E1 (EI309-481, SEQ ID NO: 10), and a 3’-UTR (SEQ ID NO: 19). The RdRP-GDD motif of the above WT replicon was further mutated to GAA, resulting a GAA mutant replicon (Fig. 20).
[0131] The expression level of the luciferase reporter was detected by the Luciferase assay. As shown in Fig. 2D, obvious luciferase induction was observed in BHK-21 cells after WT saRNA transfection, while mutating GDD into GAA leads to the total abolishment of the catalytic activity. This confirmed that the translation of sub-genomic RNA is dependent on the replication activity of saRNA.
[0132] Example 3. SaRNAs with codon optimized p200
[0133] The GO content of the RuV genome is about 70%, which is nearly the highest among RNA viruses (Auewarakul, 2005; Bennett et al., 2020). To decrease the GC ratio and enhance the expression, the p200 region was codon optimized at nucleotides encoding amino acid residues 218-237 and 419-2116 (P200-Qpti, Fig. 3A). The nucleotide sequences encoding the p200 polypeptide after the codon optimization is shown as SEQ ID NO: 12. After the optimization, the GC ratio was decreased from 70% to 57%, and it was observed that luciferase activity was decreased concurrently, although it then reached a similar level to WT at 72h post transfection (Fig. 3B). This suggests that not only the p200 protein itself but the RNA sequence or the secondary structure of the p200 is also crucial for the replication activity, and that optimization of the p200 coding sequence did not enhance the activity of saRNA.
[0134] Example 4. SaRNAs with various truncated capsid
[0135] The full length capsid (CFL) and the first 10 amino acids of E2 were deleted from the P200- OPti replicon, to produce P200-Qpti-AC. It was found that such deletion caused luciferase activity to be completely abolished (Fig. 3B). This suggests the capsid may play an important role in the saRNA replication and translation. To further investigate which region of the capsid is necessary for the activity of the saRNA, the structure of capsid was predicted using AlphaFold2 described in Mirdita et al., 2022 (Fig. 4A). Amino acid residues 1-34 were predicted as an N-terminal hydrophobic a-helix motif, which may act for membrane and p150 associations, and amino acid residues 281-300 were predicted to contain the transmembrane region and signalling peptidase recognition site. Thus, saRNA replicons with various truncation in the capsid region were constructed based on the WT (Fig 4B). For example, AC represents a replicon in which the whole capsid was deleted, AC35-270 means amino acid residues 35-270 of the capsid were deleted. All saRNAs with truncated capsid showed decreased luciferase production compared to WT saRNA replicon (Fig. 4C). This suggests that full-length capsid is necessary for the saRNA replication and translation.
[0136] Example 5. SaRNAs with various truncated E1
[0137] Optimization of the 3’ terminus of RuV saRNA was also investigated. The WT saRNA replicon 3’ -terminus contains a 522-nucleotide E1 (encoding amino acid residues 309-481 of E1 with a stop codon) and a 59-nucleotide 3’-untranslated region (UTR). The secondary structure of the last 305 nucleotides (including the last 291 nucleotides of E1 and 59 nucleotides 3’-UTR) of the replicon was predicted using the method described in Bellaousov et al., 2013 (Fig. 5A).
[0138] A series of 3’ optimization saRNA replicons were constructed based on WT, in which a stop codon was inserted before E1 , the F2A sequence was removed and E1 was truncated into fragments with different lengths (Fig. 5B). Finally, replicons including the last 305 (SEQ ID NO: 13 plus SEQ ID NO:19), 250 (SEQ ID NO:14 plus SEQ ID NO:19), 215 (SEQ ID NO:15 plus SEQ ID NO:19), 132 (SEQ ID NO:16 plus SEQ ID NO:19), 112 (SEQ ID NO:17 plus SEQ ID NO:19), 94 (SEQ ID NO:18 plus SEQ ID NO:19) and 59 nucleotides (SEQ ID NO:19) at the 3’-terminus were obtained. In these truncated replicons, a stop codon (as a part of the protein of interest) was included before E1 , so that E1 cannot be translated, thus played its function by forming RNA secondary structure. Among these, the replicons maintaining at least the last 250 nucleotides (i.e., replicons 3’-305 and 3’-250) exhibited the highest luciferase production, while other replicons (i.e., replicons 3’-112, 3’-132, and 3’-215) showed comparable or reduced activity compared to WT (Fig. 5C, D). Removal of the whole E1 (i.e., replicon 3’-59) or maintaining only the last 35 nt of E1 (i.e., 3’-94) completely abolished the activity, like the GAA mutant (Fig. 5C). It suggests that the RNA secondary structure but not the primary amino acid sequence of E1 played an important function in saRNA replication and translation.
[0139] Example 6. SaRNAs with various cap structures Different viruses have their own 5’ cap structures, including cap-0 (i.e., m7GpppNp) and cap- 1 (m7GpppNm2'-op). The 5’cap of RuV is cap-0. Hence, different kinds of cap analogs, CleanCap AU (m7GpppAmU) and AG (m7GpppAmG) purchased from TriLink Biotechnologies, were also tested in the WT saRNA. It was observed that RuV saRNA replicon with a CleanCap AG showed comparable strong luciferase activity compared to that with no modified cap, while the replicon with a CleanCap AG showed reduced but still acceptable luciferase activity up to 96 hours post transfection in BHK21 cells (Fig. 6A). In Vero cells, the RuV saRNA replicon with no modified cap showed the strongest luciferase activity, while replicons with CleanCap AU and AG showed reduced activity (Fig. 6B).
[0140] Example 7. Immune response of the SaRNAs
[0141] The RuV 3’ -250 saRNA replicon obtained in Example 5 and a Venezuelan equine encephalitic virus (VEEV) saRNA replicon were tested to examine the immune response in dendritic cells. The VEEV saRNA replicon is the only replicon that is currently used in an approved saRNA vaccine and was used as a positive control in this example. Both saRNAs were prepared by standard commercial ready to use lipid-based nanoparticles invivojet (Polyplus, Cat #101000122) and extracellular vesicle from red blood cells (RBCEV) methods and were transfected to DC2.4 mouse dendritic cells, and the luciferase activity was measured at 24 hours and 48 hours after the transfection (Fig 7A).
[0142] Both saRNAs demonstrated robust luciferase activity in DC2.4 cells after 24-48 hours. There is no significant difference in levels between RuV and VEEV based saRNAs at 24 hours using Invivojet, although VEEV showed a higher activity than RuV at 48 hours (Fig 7B, C). In contrast, the opposite trend was observed with the RBCEV method, wherein the VEEV exhibited higher activity than RuV at 24 hours and then became comparable with RuV at 48 hours (Fig 7B, C).
[0143] The two saRNAs were also tested for their pro-inflammatory cytokine profiles. VEEV saRNA induced a significant higher level of interferon-p (IFN-P) compared to RuV (Fig 7D). Both RuV and VEEV saRNAs induced similar levels of interferon-a (IFN-a) and tumour necrosis factor a (TNF- a) (Fig 7E, F). Moreover, on examination of the cells at 48 hours post transfection via light microscopy, VEEV saRNA exhibited more cell death compared to cells transfected with RuV saRNA in both formulations (Fig 7G). These results suggest that RuV saRNA may have different immunization kinetics and a better safety profile than the VEEV counterpart.
[0144] The activity of the two saRNAs were tested in vivo, and both showed comparable effective expression of the Gaussia reporter gene in mice (Fig.8). It suggests that, regardless of the formulation method (either by Invivojet or RBCEV), the RuV saRNA is able to actively express the target gene over a long period of time (>13 days) in mice.
[0145] Example 8. The Trans amplifying RNA (taRNA) system
[0146] This example tested the effect of taRNA system, which is a bipartite vector system includes a trans-replicon where one RNA encodes a gene of interest (such as saRNA), while a second RNA (the non-replicating RNA (nrRNA) or a second saRNA) supplies the replicase. From the vaccine development perspective, the taRNA system may offer advantages over saRNA in terms of safety, versatility, and manufacturing.
[0147] Two vectors were used in this example. One was the GAA mutant replicon encoding Gaussia (as an example of gene of interest), and the other one was a 3’-250 mCherry saRNA replicon which supplies RdRP. The 3’-250 mCherry saRNA replicon was obtained by replacing the Gaussia reporter gene in the RuV 3’-250 saRNA replicon obtained in Example 5 with a mCherry reporter gene.
[0148] BHK21 cells were seeded in 24-well plate, and transfected with GAA mutant (300 ng per well), 3’ -250 mCherry (300 ng per well) saRNA replicon separately, or co-transfected with these two saRNA replicons (Fig. 9A). Cell culture media was changed after 3 days post transfection. Supernatant of the cell culture at various time points were collected to measure the luciferase activity. Compared to BHK21 cells transfected with each replicon individually, cells with cotransfection showed stronger luciferase activity at all time points (Fig. 9B).
[0149] Sequences mentioned in the present invention are summarized in Table 1 below.
[0150] Table 1. Sequence listing
[0151] For one skilled in the art, various modifications and changes may be made to the present disclosure. Those skilled in the art should understand that any amendments, equivalent replacements, improvements, and so on, made within the spirit and principle of the present disclosure, should be covered within the scope of protection of the present disclosure.
[0152] Bibliography
[0153] 1. Auewarakul P. Composition bias and genome polarity of RNA viruses. Virus Res. 2005 Apr;109(1):33-7. doi: 10.1016 / j.virusres.2004.10.004. Epub 2004 Nov 18.
[0154] 2. Bellaousov S, Reuter JS, Seetin MG, Mathews DH. RNA structure: Web servers for RNA secondary structure prediction and analysis. Nucleic Acids Res. 2013 Jul;41(Web Server issue):W471-4. doi: 10.1093 / nar / gkt290. Epub 2013 Apr 24.
[0155] 3. Bennett AJ, Paskey AC, Ebinger A, Pfaff F, Priemer G, Hoper D, Breithaupt A, Heuser E, Ulrich RG, Kuhn JH, Bishop-Lilly KA, Beer M, Goldberg TL. Relatives of rubella virus in diverse mammals. Nature. 2020 Oct;586(7829):424-428. doi: 10.1038 / s41586-020-2812- 9. Epub 2020 Oct 7. Erratum in: Nature. 2020 Dec;588(7836):E2.
[0156] 4. Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nat Methods. 2022 Jun;19(6):679-682. doi: 10.1038 / S41592-022-01488-1. Epub 2022 May 30.
[0157] 5. Ramos da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, Porchia BFMM, Moreno ACR, Aps LRMM, Venceslau-Carvalho AA, Tombacz I, Fotoran WL, Kariko K, Lin PJC, Tam YK, de Oliveira Diniz M, Pardi N, de Souza Ferreira LC. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med. 2023 Mar 8;15(686):eabn3464. doi: 10.1126 / scitranslmed.abn3464. Epub 2023 Mar 8.
[0158] 6. Tan YB, Law MCY, Luo D. Targeting the alphavirus virus replication process for antiviral development. Antiviral Res. 2023 Feb;210:105494. doi: 10.1016 / j. antiviral.2022.105494. Epub 2022 Dec 24.
Claims
Claims1. A Rubivirus based self-amplifying RNA (saRNA) comprising:(i) a first polynucleotide comprising a 5’-untranslated region (5’-UTR) of the Rubivirus;(ii) a second polynucleotide encoding a full length p200 polypeptide of the Rubivirus;(iii) a third polynucleotide comprising a subgenomic promoter of the Rubivirus;(iv) a fourth polynucleotide encoding a full length capsid protein of the Rubivirus;(v) a fifth polynucleotide encoding at least the first 10 amino acids of the E2 protein of the Rubivirus;(vi) a sixth polynucleotide encoding a first protein of interest;(vii) a seventh polynucleotide comprising at least the last 53 nucleotides of the E1 coding sequence of the Rubivirus; and(viii) an eighth polynucleotide comprising a 3’-UTR of the Rubivirus.
2. The saRNA according to claim 1, wherein the Rubivirus is a Rubella virus (RuV), a Ruhugu virus (RuhV) or a Rustrela virus (RusV).
3. The saRNA according to claim 1 , wherein the Rubivirus is a RuV selected from a group consisting of RA 27 / 3 strain, HPV77 / DE5 strain, Cendehill strain, M33 strain, Therien strain, Thomas strain and IB2 strain.
4. The saRNA according to claim 1, wherein the first polynucleotide comprises, or consists of, the nucleotide sequence as shown in SEQ ID NO: 22.
5. The saRNA according to claim 1, wherein the full length p200 polypeptide consists of an amino acid sequence as shown in SEQ ID NO: 2.
6. The saRNA according to claim 1 , wherein the second polynucleotide comprises, or consists of, a nucleotide sequence as shown in SEQ ID NO: 3 or SEQ ID NO: 12.
7. The saRNA according to claim 1, wherein the full length capsid consists of an amino acid sequence as shown in SEQ ID NO: 4.
8. The saRNA according to claim 1 , wherein the first 10 amino acids of E2 protein consist of SEQ ID NO: 6.
9. The saRNA according to claim 1 , wherein the seventh polynucleotide comprises, or consists of, a nucleotide sequence as shown in SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 or SEQ ID NO: 17.
10. The saRNA according to claim 1 , wherein the eighth polynucleotide comprises, or consists of, the nucleotide sequence as shown in SEQ ID NO: 19.11 . The saRNA according to claim 1 , wherein the subgenomic promoter comprises, or consists of, the nucleotide sequence as shown in SEQ ID NO: 24.
12. The saRNA according to any one of claims 1-11 , further comprising a 5’-cap, a 3’-poly A tail, and / or a polynucleotide encoding a hepatitis delta virus ribozyme (HDVr).
13. The saRNA according to claim 12, wherein the cap is a non-modified cap m7GpppNp, a CleanCap AU (rn7GpppAmU), or a CleanCap AG (rn7GpppAmG).
14. The saRNA according to any one of claims 1-13, wherein the first polynucleotide consists of the nucleotide sequence as shown in SEQ ID NO: 22, the second polynucleotide consists of the nucleotide sequence as shown in SEQ ID NO: 3, the third polynucleotide consists of the nucleotide sequence as shown in SEQ ID NO: 24, the fourth polynucleotide encodes the amino acid sequence of SEQ ID NO: 4, the fifth polynucleotide encodes at least the first 10 amino acids of E2 protein as shown in SEQ ID NO: 6, the seventh polynucleotide consists of the nucleotide sequence as shown in SEQ ID NO: 14, and the eighth polynucleotide consists of the nucleotide sequence as shown in SEQ ID NO: 19.
15. The saRNA according to any one of claims 1-14, further comprising a ninth polynucleotide encoding a second protein of interest.
16. The saRNA according to any one of claims 1-15, wherein the protein of interest is a reporter protein, a virus antigen, a bacteria antigen, or a tumor antigen.
17. A vector comprising a polynucleotide molecule encoding the saRNA according to any one of claims 1-16.
18. A trans amplifying RNA (taRNA) system based on Rubivirus comprising:(a) a saRNA and a non-replicating RNA (nrRNA), wherein the saRNA comprises 5’-UTR of the Rubivirus, a polynucleotide comprising a subgenomic promoter of the Rubivirus, apolynucleotide encoding a full length capsid of the Rubivirus, a polynucleotide encoding at least the first 10 amino acids of E2 protein of the Rubivirus, a polynucleotide encoding a protein of interest, a polynucleotide comprising the last 53 nucleotides of E1 protein of the Rubivirus, and a polynucleotide comprising 3’-UTR of the Rubivirus, the nrRNA comprises a polynucleotide encoding a full length p200 polypeptide of the Rubivirus which provides a RNA dependent RNA Polymerase, or(b) a saRNA and a nrRNA, wherein the saRNA comprises 5’-UTR of the Rubivirus, a polynucleotide comprising a subgenomic promoter of the Rubivirus, a polynucleotide encoding a protein of interest, a polynucleotide comprising the last 53 nucleotides of E1 protein of the Rubivirus, and a polynucleotide comprising 3’-UTR of the Rubivirus, and the nrRNA comprises a polynucleotide encoding a full length p200 polypeptide of the Rubivirus which provides a RNA dependent RNA Polymerase and a polynucleotide encoding a full length capsid of the Rubivirus, or(c) two saRNAs, wherein each saRNA comprises 5’-UTR of the Rubivirus, a polynucleotide encoding a full length p200 polypeptide of the Rubivirus which provides a RNA dependent RNA Polymerase, a polynucleotide comprising a subgenomic promoter of the Rubivirus, a polynucleotide encoding a full length capsid of the Rubivirus, a polynucleotide encoding at least the first 10 amino acids of E2 protein of the Rubivirus, a polynucleotide comprising the last 53 nucleotides of E1 protein of the Rubivirus, and a polynucleotide comprising 3’-UTR of the Rubivirus, wherein one saRNA further comprises a polynucleotide encoding a protein of interest.
19. A composition comprising the saRNA according to any one of claims 1-16 or the vector according to claim 17 or the taRNA system according to claim 18, and a pharmaceutically acceptable carrier.
20. The composition according to claim 19, wherein the saRNA is encapsulated in, bound to, or absorbed on any one of a cationic lipid, a liposome, a lipid nanoparticle, a polyplex, a cochleate, a virosome, an immune-stimulating complex, a red blood cell-derived extracellular vesicles (RBCEV), a microparticle, a microsphere, a nanosphere, a unilamellar vesicle, a multilamellar vesicle, an oil-in-water emulsion, a water-in-oil emulsion, an emulsome, a polycationic peptide, and a cationic nanoemulsion, or a combination thereof.
21. The composition according to any one of claims 19-20, wherein the composition is a prophylactic or a therapeutic vaccine.
22. The composition according to claim 21 , wherein the vaccine is a therapeutic vaccine for treatment of cancer.
23. A method for inducing an immune response in a subject, comprising administrating an effective amount of the saRNA according to any one of claims 1-16 or the vector according to claim 17 or the taRNA system according to claim 18, or the composition according to any one of claims 19-21 to the subject.
24. The method according to claim 23, wherein the protein of interest is a virus antigen or a bacteria antigen.
25. The method according to claim 24, wherein the virus antigen is selected from a group consisting of a SARS-CoV-2 antigen, a Hepatitis B virus (HBV) antigen, an influenza virus hemagglutinin (HA) antigen, a Varicella-Zoster Virus (VZV) antigen, a SARS-CoV-1 antigen, a Middle East Respiratory Syndrome (MERS) coronavirus antigen, an Epstein-Barr virus (EBV) antigen, a herpes simplex virus (HSV) antigen, a rabies virus antigen, a cytomegalovirus (CMV) antigen, a human immunodeficiency virus (HIV) antigen, a Zika virus antigen, a respiratory syncytial virus (RSV) antigen, and a human papillomavirus (HPV) antigen; and the bacteria antigen is selected form a group consisting of a Mycobacterium tuberculosis antigen, a Chlamydia trachomatis antigen, a Staphylococcus aureus antigen, a Streptococcus pneumonia antigen, a Neisseria meningitidis antigen, a Clostridium tetani antigen, and a Corynebacterium diphtheriae antigen.
26. A method for treating a cancer in a subject, comprising administrating an effective amount of the saRNA according to any one of claims 1-16 or the vector according to claim 17 or the taRNA system according to claim 18 or the composition according to any one of claims 19- 21 to the subject.
27. The method according to claim 26, wherein the protein of interest is a tumor antigen.
28. The method according to claim 27, wherein the tumor antigen is selected from the group consisting of ovalbumin (OVA), ovalbumin, Wilms’ tumor 1 (WT1), Mucin 1 , human epidermal growth factor receptor 2 (HER2), Prostate acid phosphatase (PAP) protein.
29. Use of the saRNA according to any one of claims 1-16 or the vector according to claim 17 or the taRNA system according to claim 18 in the manufacture of a medicament for inducing an immune response.
30. Use of the saRNA according to any one of claims 1-16 or the vector according to claim 17 or the taRNA system according to claim 18 in the manufacture of a medicament for treating a cancer.
Citation Information
Patent Citations
Highly infectious rubella virus DNA constructs and methods of production
US20030130498A1
Live, attenuated rubella vector to express vaccine antigens
WO2013152352A1
Flexible expression vector systems and application of same to vaccines and immunotherapeutics
WO2022246559A1
